Unresectable Non-metastatic Hepatocellular Carcinoma
Oncology
Prevalence
12.0 / 100K
Incidence
8.6 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| Zavedos® | Merus N.V. (MRUS) |
Frequently asked questions
How many drugs are in development for Unresectable Non-metastatic Hepatocellular Carcinoma?
BioSniper tracks 1 drug in development for Unresectable Non-metastatic Hepatocellular Carcinoma across 1 company.
How many clinical trials target Unresectable Non-metastatic Hepatocellular Carcinoma?
There are 1 clinical trial targeting Unresectable Non-metastatic Hepatocellular Carcinoma tracked by BioSniper.
What is the prevalence of Unresectable Non-metastatic Hepatocellular Carcinoma?
The estimated prevalence of Unresectable Non-metastatic Hepatocellular Carcinoma is approximately 12.0 per 100,000 population.
Deep-dive into Unresectable Non-metastatic Hepatocellular Carcinoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis